Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

"Vertex reports long-term results for Casgevy in sickle cell and thalassaemia" was originally created and published by ...

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) recently received approval from the European Commission for ALYFTREK, enhancing its reach in European markets with new reimbursement agreements in Ireland and ...

While BMO Capital Markets said that zimislecel is “highly encouraging” for type 1 diabetes, questions regarding its target ...

VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years and older.

Vertex Pharmaceuticals may have narrowed its focus this year, but the biopharma’s decision to stick with its remaining islet ...

Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek ...

Review which funds and institutions currently hold Vertex Pharmaceuticals Inc (VRTX:XNAS) stock for ownership information.

Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a rare and progressive genetic disease, expanding the company’s presence ...